{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:03:45Z","timestamp":1775484225521,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,6,25]],"date-time":"2013-06-25T00:00:00Z","timestamp":1372118400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1038\/bjc.2013.318","type":"journal-article","created":{"date-parts":[[2013,6,25]],"date-time":"2013-06-25T20:06:11Z","timestamp":1372190771000},"page":"1593-1598","source":"Crossref","is-referenced-by-count":17,"title":["BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance"],"prefix":"10.1038","volume":"109","author":[{"given":"W T","family":"Parker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A L","family":"Yeoman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B A","family":"Jamison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D T","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H S","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T P","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Branford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,25]]},"reference":[{"key":"BFbjc2013318_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature09650","volume":"469","author":"K Anderson","year":"2011","unstructured":"Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, Kempski H, Moorman AV, Titley I, Swansbury J, Kearney L, Enver T, Greaves M (2011) Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469: 356\u2013361.","journal-title":"Nature"},{"key":"BFbjc2013318_CR2","first-page":"93","volume-title":"Myeloid Leukemia: Methods and Protocols, Methods in Molecular Medicine","author":"S Branford","year":"2006","unstructured":"Branford S, Hughes T (2006a) Detection of BCR-ABL mutations and resistance to imatinib mesylate. In Myeloid Leukemia: Methods and Protocols, Methods in Molecular Medicine, Illand H, Hertzgerg M, Marlton P (eds) Vol. 125, pp 93\u2013106. Totawa, Humana Press: New Jersey."},{"key":"BFbjc2013318_CR3","first-page":"69","volume-title":"Myeloid Leukemia: Methods and Protocols, Methods in Molecular Medicine","author":"S Branford","year":"2006","unstructured":"Branford S, Hughes T (2006b) Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. In Myeloid Leukemia: Methods and Protocols, Methods in Molecular Medicine, Illand H, Hertzgerg M, Marlton P (eds) Vol. 125, pp 69\u201392. Humana Press: Totawa, New Jersey."},{"key":"BFbjc2013318_CR4","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","volume":"114","author":"S Branford","year":"2009","unstructured":"Branford S, Melo JV, Hughes TP (2009) Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114: 5426\u20135435.","journal-title":"Blood"},{"key":"BFbjc2013318_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481: 506\u2013510.","journal-title":"Nature"},{"key":"BFbjc2013318_CR6","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","volume":"120","author":"JB Egan","year":"2012","unstructured":"Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, Keats JJ, Fonseca R, Bergsagel PL, Craig DW, Carpten JD, Stewart AK (2012) Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 120: 1060\u20131066.","journal-title":"Blood"},{"key":"BFbjc2013318_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/leu.2011.187","volume":"26","author":"FX Gruber","year":"2012","unstructured":"Gruber FX, Ernst T, Porkka K, Engh RA, Mikkola I, Maier J, Lange T, Hochhaus A (2012) Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients. Leukemia 26: 172\u2013177.","journal-title":"Leukemia"},{"key":"BFbjc2013318_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2010.030999","volume":"96","author":"B Hanfstein","year":"2011","unstructured":"Hanfstein B, Muller MC, Kreil S, Ernst T, Schenk T, Lorentz C, Schwindel U, Leitner A, Hehlmann R, Hochhaus A (2011) Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica 96: 360\u2013366.","journal-title":"Haematologica"},{"key":"BFbjc2013318_CR9","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","volume":"27","author":"T Hughes","year":"2009","unstructured":"Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, Muller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A (2009) Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 27: 4204\u20134210.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013318_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","volume":"121","author":"JS Khorashad","year":"2013","unstructured":"Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, Alikian M, Reid AG, Foroni L, Marin D, Druker BJ, O'Hare T, Deininger MW (2013) BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 121: 489\u2013498.","journal-title":"Blood"},{"key":"BFbjc2013318_CR11","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1126\/science.1164266","volume":"322","author":"CG Mullighan","year":"2008","unstructured":"Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, Downing JR (2008) Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322: 1377\u20131380.","journal-title":"Science"},{"key":"BFbjc2013318_CR12","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O'Hare","year":"2005","unstructured":"O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65: 4500\u20134505.","journal-title":"Cancer Res"},{"key":"BFbjc2013318_CR13","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1200\/JCO.2011.35.0934","volume":"29","author":"WT Parker","year":"2011","unstructured":"Parker WT, Lawrence RM, Ho M, Irwin DL, Scott HS, Hughes TP, Branford S (2011) Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J Clin Oncol 29: 4250\u20134259.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013318_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1182\/blood-2012-04-427039","volume":"121","author":"B Parkin","year":"2013","unstructured":"Parkin B, Ouillette P, Li Y, Keller J, Lam C, Roulston D, Li C, Shedden K, Malek SN (2013) Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood 121: 369\u2013377.","journal-title":"Blood"},{"key":"BFbjc2013318_CR15","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood-2009-09-245381","volume":"115","author":"FX Schaub","year":"2010","unstructured":"Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda RC (2010) Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 115: 2003\u20132007.","journal-title":"Blood"},{"key":"BFbjc2013318_CR16","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, Muller MC, Ernst T, Rosti G, Porkka K, Baccarani M, Cross NC, Martinelli G (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118: 1208\u20131215.","journal-title":"Blood"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2013318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2013318","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2013318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:15:25Z","timestamp":1684415725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2013318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,25]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["BFbjc2013318"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2013.318","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,25]]}}}